Archives of Business Research – Vol. 13, No. 05
Publication Date: May 25, 2025
DOI:10.14738/abr.1305.18834.
Perez-Espinosa, M., Khanfar, N. M., Attarabeen, O. F., Pham, H., Silva-Suarez, G., & Mujtaba, B. G. (2025). Marketing Buprenorphine for Chronic Pain Management: Overcoming Societal Perceptions and Enhancing Public Health. *Archives of Business Research, 13*(05). 125-142.

Marketing Buprenorphine for Chronic Pain Management: Overcoming Societal Perceptions and Enhancing Public Health

Marc Perez-Espinosa
ORCID: 0009-0000-7397-2052
PhD Candidate, Barry and Judy Silverman College of Pharmacy,
Department of Sociobehavioral and Administrative Pharmacy,
Nova Southeastern University (USA)

Nile M. Khanfar
ORCID: 0000-0002-2828-6499
PhD, Associate Professor, Barry and Judy Silverman College of Pharmacy,
Department of Sociobehavioral and Administrative Pharmacy,
Nova Southeastern University

Omar F. Attarabeen
ORCID: 0000-0001-7548-3404
PhD, Associate Professor, Department of Pharmacy Practice &
Administration, School of Pharmacy and Health Professions (SOPHP),
University of Maryland Eastern Shore (USA) 30920 College Backbone Rd.,
Room # 2121. Princess Anne, MD 21853

Huy Pham
ORCID: 0000-0002-8409-9655
PharmD, Associate Professor,
Barry and Judy Silverman College of Pharmacy,
Department of, Department of Pharmacy Practice,
Nova Southeastern University (USA), Ft. Lauderdale

Georgina Silva-Suarez
ORCID: 0000-0001-7295-7221
PhD, Assistant Professor, Department of Sociobehavioral
and Administrative Pharmacy, Nova Southeastern University,
San Juan, Puerto Rico Professional Offices Park IV
998 San Roberto St. San Juan, PR 00926

Bahaudin G. Mujtaba
ORCID: 0000-0003-1615-3100
D.B.A., Professor, College of Business and Entrepreneurship,
Nova Southeastern University, USA Huizenga College of Business
and Entrepreneurship 3301 College Avenue. Fort Lauderdale,
FL. 33314. USA

ABSTRACT

As a partial mu-opioid receptor agonist, buprenorphine is safe and effective in lowering the risk of opioid dependency, making it a valuable tool for treating pain. Buprenorphine's comparative advantages over typical opioids—such as a lower risk of abuse and a good safety profile—are highlighted in the literature review. Despite these advantages, medical and cultural stigma prevents eligible patients from effectively using this medicine. As such, stigma impacts both healthcare providers' views toward prescribing this medication and patients' access to therapy. Using a methodology of thoroughly understanding buprenorphine's potential to redefine therapeutic strategies in public health, this study examines the pharmacological foundations, compare its efficacy and safety with other analgesics, and explore remedies for the stigmas associated with its use This exploratory paper, through literature review of existing data, investigates the multifaceted role of buprenorphine in the management of chronic pain and treating opioid use disorder, emphasizing the challenges posed by stigma and regulatory barriers. This study's findings lead to a discussion of how academics and marketers may improve public awareness and proper use of buprenorphine by developing educational initiatives. It is recommended that marketers create focused educational initiatives for the public and healthcare professionals with the goal of changing public opinion and raising awareness of buprenorphine as an essential treatment option. It is the responsibility of academics to close research gaps, especially in the areas of understanding and combating stigma via empirical investigations and the use of theoretical frameworks such as the Health Belief Model. The original study advocates for a comprehensive strategy that combines legislative change, activism, and ongoing research to optimize buprenorphine's potential and enhance public health outcomes related to pain treatment and opiate addiction.

Keywords: chronic pain, perception, buprenorphine, marketing, opioid use disorder, Health Belief Model.

JEL Classification: I10, I12, I18, D83

INTRODUCTION

In the world of healthcare, effectively managing chronic pain and combating Opioid Use Disorder (OUD) are among the most significant challenges facing clinicians and patients alike (Cheetham et al., 2022). Chronic pain, a pervasive condition affecting a significant portion of the global population, is not only a major cause of disability, but also a profound contributor to healthcare utilization and economic burden (Lazaridou et al., 2020). Simultaneously, the opioid crisis continues to escalate, with an alarming increase in opioid misuse and dependence, leading to significant morbidity and mortality worldwide (Whelan and Remski, 2012). These intertwined public health issues necessitate a balanced approach to pain management, safety, and wellness that also mitigates the potential for addiction (Javed et al., 2024; Mujtaba and Myers, 2022; Khanfar et all., 2024).

Buprenorphine, a partial mu-opioid receptor agonist, represents a critical advancement in this pursuit. Its distinct pharmacological characteristics hold great potential for treating OUD as a safer substitute for full opioid agonists and as a potent analgesic. Buprenorphine, in contrast to conventional opioids, lowers cravings for opioids and effectively relieves pain without carrying

a high risk of producing euphoric effects that can result in opioid misuse and dependency (Kumar et al., 2023). This dual utility makes buprenorphine a pivotal component in the modern pharmacotherapy arsenal against chronic pain and opioid addiction.

The development and increasing use of buprenorphine in clinical settings reflect a growing acknowledgment of its benefits. However, the potential of buprenorphine is not fully realized, often overshadowed by persistent stigma and misunderstandings related to its use. Misconceptions about its safety, effectiveness, and risk of dependency continue to hinder its broader acceptance and integration into pain management and addiction treatment protocols (Steenhof and Ng, 2024).

This paper aims to explore the complexities surrounding the use of buprenorphine in chronic pain management and its role in addressing OUD. Through providing a thorough understanding of buprenorphine's potential to redefine therapeutic strategies in these crucial areas of public health, this discussion will examine the pharmacological foundations, compare its efficacy and safety with other analgesics, and discuss the societal and medical stigmas associated with its use. The paper will argue for a more nuanced understanding and use of buprenorphine through an integrative assessment of recent research and clinical practices. It will also advocate for changes to legislative and educational initiatives to improve buprenorphine's acceptance and maximize its therapeutic impact.

Historical Development of Buprenorphine

Buprenorphine’s development marked a significant milestone in the pharmacological management of both chronic pain and OUD. Initially synthesized in 1966 by Reckitt and Colman, buprenorphine was the result of a rigorous search for safer pain relief alternatives that could offer significant analgesic properties with a lower risk of respiratory depression (Heidbreder et al., 2023). Preliminary investigations revealed that buprenorphine exhibited a distinct propensity for binding to mu-opioid receptors, functioning as a partial agonist. This property differentiated it significantly from other opioids available at the time, as it suggested a lower potential for abuse and reduced respiratory risks. These encouraging outcomes encouraged more research and the ultimate release of buprenorphine on the medicinal market.

In 1978, buprenorphine was introduced in the United Kingdom as Temgesic, an analgesic for moderate to severe pain, and gradually gained approval across Europe and other parts of the world. The drug's unique properties and effectiveness in pain management quickly made it a valuable tool in clinical settings. However, it was not just the drug's efficacy as a pain reliever that captured the attention of the medical community; but also its potential role in effectively treating opioid dependency (Johnson et al., 2005).

By the 1980s, the escalating problem of opioid addiction, particularly in the United States, prompted researchers to explore buprenorphine's effectiveness in addiction treatment (Silvis et al., 2022). Studies demonstrated that buprenorphine could reduce drug craving and withdrawal symptoms without producing the adverse effects associated with other opioids (Silvis et al., 2022). These findings led to the development of formulations combining buprenorphine with naloxone, a drug that counters the effects of opioids and helps prevent misuse. This combination, marketed as Suboxone®, was approved in the early 2000s in the

URL: http://doi.org/10.14738/abr.1305.18834

United States and has since played a crucial role in opioid addiction treatment programs (Whelan and Remski, 2012). The approval of Suboxone marked a turning point, providing a new, more manageable treatment option for individuals struggling with opioid dependence. It allowed for treatment outside the confines of specialized clinics, extending care to primary health settings and enhancing the accessibility and convenience of treatment for patients (Sivils et al., 2022).

Throughout its history, buprenorphine has been subject to various studies and regulatory changes that have shaped its use and distribution. Its inclusion in numerous international narcotics control regimes and scheduling under the Controlled Substances Act are reflections of continuous efforts to strike a balance between its potential hazards and clinical advantages. In recent developments, the Consolidation Appropriations Act of 2023 has made significant strides in improving access to buprenorphine by removing the X-waiver requirement for prescribers. This legislative change represented a crucial step toward easing the regulatory barriers that have historically limited the use of this valuable medication in treating opioid use disorder and chronic pain.

Pharmacological Properties of Buprenorphine

Buprenorphine's primary mechanism of action is its partial agonism at the mu-opioid receptors, a key site for opioid activity within the central nervous system. Unlike full agonists such as morphine and methadone, buprenorphine exhibits a high affinity but low intrinsic activity at these receptors. This unique interaction allows it to provide adequate pain relief and reduce opioid cravings without the high potential for abuse typical of full agonists. The ceiling effect of buprenorphine, particularly on respiratory depression, significantly enhances its safety profile. At therapeutic doses, even if the dosage is increased, the risk of respiratory depression does not proportionally escalate, making it a safer option in both pain management and opioid replacement therapy (Kumar et al., 2023).

The partial agonist property also results in less euphoria and a lower potential for dependency compared to full agonists, which has made buprenorphine a favored option in the long-term management of both chronic pain and opioid dependence. However, its ability to displace full agonists from the mu-opioid receptors can precipitate withdrawal in opioid-dependent individuals if not adequately managed, illustrating the need for careful dosing and monitoring when initiating buprenorphine treatment (Ling et al., 2021).

In addition to its action on mu-opioid receptors, buprenorphine is an antagonist at kappa-opioid receptors. Antidepressant and anxiolytic effects linked to antagonistic interactions at these receptors are advantageous in treating the psychological components of addiction and chronic pain. Since the dysphoric and psychotomimetic effects of several opioids have been linked to kappa receptors, buprenorphine's capacity to inhibit these receptors may enhance its overall therapeutic profile by lowering the risk of these side effects (Johnson et al., 2005).

Buprenorphine's pharmacokinetics are characterized by its slow dissociation from the mu-opioid receptors, which contributes to its long-lasting effects and makes it suitable for once-daily dosing in most formulations. This slow dissociation, combined with its partial agonist activity, helps maintain stable plasma levels and minimize withdrawal symptoms between

doses. Buprenorphine undergoes extensive first-pass metabolism in the liver primarily via the cytochrome P450 3A4 enzyme, resulting in low bioavailability when administered orally. This pharmacokinetic property led to the development of sublingual and transdermal delivery systems, which bypass the first-pass effect and improve bioavailability (Whelan and Remski, 2012).

Different formulations of buprenorphine are available to tailor its distribution to the needs of distinct patient populations. To lower the danger of diversion and misuse, sublingual tablets and films that mix buprenorphine and naloxone are frequently utilized in the treatment of opioid dependence. When taken sublingually as directed, the naloxone component functions as an opioid antagonist and is clinically inert; however, if the formulation is injected, it causes withdrawal symptoms, which discourages overuse (Heidbreder et al., 2023).

Buprenorphine is FDA-approved for pain relief as a transdermal patch (Butrans) and buccal film (Belbuca), which offers continuous drug delivery for a prolonged amount of time. These forms of delivery are perfect for chronic illnesses that need steady, long-term treatment. By reducing the peaks and troughs in drug levels linked to shorter-acting analgesics, these delivery routes enhance patient compliance and comfort while also increasing pain control (Sivils et al., 2022).

Clinical Implications of Buprenorphine

Buprenorphine's unique profile as a partial mu-opioid receptor agonist with a high affinity and slow dissociation rate offers distinct advantages in the management of chronic pain. Its ceiling effect for respiratory depression significantly enhances patient safety, particularly in populations at risk for opioid overdose or with compromised respiratory function. Unlike full agonists, buprenorphine provides analgesic effects without the high peak effects that can lead to euphoria and subsequent addiction, making it an ideal option for long-term management of chronic pain conditions (Dalal et al., 2021).

Buprenorphine's transdermal and buccal formulations enable steady-state drug delivery, preserving adequate plasma levels to relieve pain without requiring frequent dosage adjustments. By reducing oscillations in pain intensity and offering consistent pain relief, the use of buprenorphine enhances patient compliance and quality of life. Furthermore, buprenorphine is a flexible analgesic for a variety of pain syndromes, from diabetic neuropathy to osteoarthritis, because of its capacity to decrease both nociceptive and neuropathic pain (Ling et al., 2021).

Because of its partial agonist characteristics, buprenorphine is a key component of medication-assisted therapy (MAT) for opioid dependency. Instead of having the reinforcing effects of high-dose opioids, it lessens cravings and withdrawal symptoms by slightly activating mu-opioid receptors compared to full agonists. This reduces the possibility of developing new addictions while aiding in the management of addiction (Whelan and Remski, 2012).

The combination of buprenorphine with naloxone in sublingual tablets or films acts as a safeguard against misuse, as naloxone precipitates withdrawal when injected, thus deterring non-prescribed routes of administration. This formulation has revolutionized outpatient

URL: http://doi.org/10.14738/abr.1305.18834

treatment for opioid dependence, allowing patients to maintain daily activities and reduce healthcare costs associated with inpatient treatment programs. Moreover, buprenorphine's safety profile, including a lower risk of overdose compared to methadone, facilitates its use in a broader range of clinical settings, from specialized addiction centers to primary care offices (Sivils et al., 2022).

The clinical use of buprenorphine is influenced by regulatory frameworks designed to balance its therapeutic benefits with potential risks of misuse. In many regions, buprenorphine is a controlled substance where its prescription is subject to specific guidelines and regulations, including provider training and certification requirements. These regulations aim to ensure that buprenorphine is used safely and effectively, maximizing its benefits while minimizing risks (Heidbreder et al., 2023). In the United States, for instance, the Drug Addiction Treatment Act (DATA) allows qualified physicians to prescribe buprenorphine in office-based settings, a significant shift from the more restrictive settings required for methadone dispensing. This has expanded access to treatment for many patients struggling with opioid addiction, reflecting a public health approach that emphasizes treatment and recovery over punitive measures (Johnson et al., 2005).

As the opioid crisis continues to evolve, so too does the role of buprenorphine in managing both pain and addiction. Ongoing research into buprenorphine's pharmacological actions may lead to new formulations or combination therapies that enhance its effectiveness or reduce side effects. Furthermore, expanding educational initiatives for healthcare providers on the use of buprenorphine can improve prescribing practices and patient outcomes. Efforts to destigmatize medication-assisted treatment (MAT), and integrate addiction treatment into broader medical practice are crucial for increasing treatment uptake and adherence. By continuing to leverage buprenorphine's clinical benefits in innovative ways, healthcare systems can better address the complexities of opioid dependence and chronic pain management, ultimately improving patient care and public health outcomes.

Stigma and Misunderstandings Surrounding Buprenorphine

Despite its clinical benefits, buprenorphine treatment is often marred by significant societal and medical stigma that can hinder patient access and adherence. Societal stigma stems from broader misconceptions about addiction as a moral failing rather than a medical condition. This stigma extends to treatments like buprenorphine, which some may view as simply substituting one addiction for another rather than recognizing it as a legitimate medical therapy. Such views can deter individuals from seeking treatment for opioid dependency for fear of judgment or discrimination (Cheetham et al., 2022).

In the healthcare setting, the stigma manifests through reluctance or outright refusal by some healthcare providers to prescribe buprenorphine (Silvis et al., 2022). This could be the result of preconceptions toward patients with substance use problems, a lack of knowledge about addiction medicine, or worries about the difficulties of maintaining treatment (Jones et al., 2023). According to Dela Cruz et al. (2023), there is a possibility that patients may have worse health outcomes as a result of this medical stigma, which affects both the quality and accessibility of therapy.

Misunderstandings about the pharmacological properties and appropriate use of buprenorphine also contribute to its underutilization. There is a lack of knowledge among some healthcare providers about how buprenorphine works, its safety profile, and its potential benefits over other opioids. This gap in knowledge can result in hesitancy to prescribe buprenorphine, especially in regions where opioid misuse is highly stigmatized (Sivils et al., 2022).

Moreover, there are misconceptions regarding the risk of dependency associated with buprenorphine. While buprenorphine is a partial agonist at the mu-opioid receptor, which makes it less likely to cause euphoria and subsequent addiction compared to full agonists, it can still be misunderstood as being just as addictive as other opioids. This misunderstanding can prevent its use in patients who could benefit from its properties, particularly in chronic pain management where opioid alternatives are needed (Chen et al., 2014).

Regulatory policies can inadvertently reinforce stigma if they impose overly strict controls that make prescribing buprenorphine burdensome. In some jurisdictions, prescribers are required to obtain special certifications or navigate complex bureaucratic processes to prescribe buprenorphine, which can dissuade clinicians from including it in their practice. While these regulations aim to curb misuse and diversion, they can also limit patient access to essential treatment, perpetuating the stigma associated with MAT (Heidbreder et al., 2023).

Despite these obstacles, buprenorphine continues to be a vital component in the combined battle against opioid abuse and chronic pain, demonstrating the influence of pharmaceutical innovation on public health (Kumar et al., 2023). Efforts to overcome the stigma associated with buprenorphine involve educational programs aimed at both the public and healthcare providers. Increasing awareness about the effectiveness of MAT and the biological basis of addiction can help reduce societal stigma. For healthcare providers, the mandated 8-hour training required to prescribe buprenorphine offers a critical opportunity to integrate information that could demystify the drug and address the societal stigma surrounding its use (Janet Ho et al., 2022). This training should not only cover the clinical aspects of buprenorphine but also emphasize its role in the broader context of addiction treatment, highlighting the science behind opioid addiction and the proven benefits of MAT. By enriching this educational content, healthcare providers can be better equipped to advocate for buprenorphine's use and encourage its broader adoption in clinical practice. Additionally, advocacy from medical associations and recovery communities can influence policy changes that streamline buprenorphine prescribing practices, making it easier for qualified clinicians to offer this treatment. These efforts can help shift the narrative around buprenorphine from one of skepticism and stigma to recognition of its value as a critical tool in the fight against opioid addiction and its role in pain management.

LITERATURE REVIEW

Buprenorphine and Chronic Pain Treatment

Buprenorphine's efficacy in chronic pain management is well-documented, with studies highlighting its advantages over traditional full agonist opioids. Dalal et al., (2021) emphasize that buprenorphine is effective for various types of pain, including neuropathic pain, which is often resistant to other opioids. This is particularly significant as neuropathic pain can be

URL: http://doi.org/10.14738/abr.1305.18834

debilitating and difficult to manage. The study suggests that buprenorphine's unique action at the kappa-opioid receptor might play a role in this effectiveness, providing relief from pain types that are not typically responsive to standard opioid treatments.

Furthermore, compared to full agonists like morphine and fentanyl, buprenorphine offers a lesser risk of dependence and side effects because of its partial agonist qualities (Ling et al., 2012). With the possibility of addiction and negative consequences, this profile makes it a desirable choice for the long-term management of chronic pain. One important factor in buprenorphine's effectiveness as a pain reliever is its safety profile.

According to Chen et al. (2014), buprenorphine is a safer option for respiratory depression than other opioids because of its ceiling effect, which can cause considerable respiratory suppression at high doses. Because of this characteristic, buprenorphine can be taken at higher doses without the same degree of overdose risk.

In addition to its respiratory safety, buprenorphine has been noted for its relatively mild side-effect profile. Johnson et al., (2005) pointed out that patients on buprenorphine report fewer cognitive impairments and less sedation, factors that can significantly affect quality of life and daily functioning in patients dealing with chronic pain.



Figure 1: Efficacy of Transdermal Buprenorphine Compared with Conventional Opioids in Patients with Chronic Cancer Pain.

Source: "Benefit-Risk Analysis of Buprenorphine for Pain Management. Journal of Pain Research," Hale, M., Garofoli, M., & Raffa, R. B. 2021. Volume 14, 1359-1369.

When compared directly with other opioids, buprenorphine shows a favorable balance of efficacy and safety. Kumar et al., (2023) highlight studies where buprenorphine provided comparable pain relief to other opioids but with fewer adverse effects and better outcomes in

terms of dependency and withdrawal symptoms. These characteristics suggest that buprenorphine could be particularly useful in populations where pain management needs to be balanced with concerns about opioid misuse or overdose



Figure 2: Adverse Events Reported in Clinical Trials of Buprenorphine Buccal Film Compared with Conventional Opioids for Chronic Pain.

Source: "Benefit-Risk Analysis of Buprenorphine for Pain Management. Journal of Pain Research, Hale," M., Garofoli, M., & Raffa, R. B. 2021. Volume 14, 1359-1369.

Furthermore, clinical trials and patient-reported outcomes consistently reflect the benefits of buprenorphine in managing chronic pain. Patients treated with buprenorphine often experience sustained pain relief with an improved overall quality of life. These outcomes are crucial for chronic pain management, where the goal is not only to reduce pain intensity but also to enhance functional status and overall well-being.

Literature strongly supports the use of buprenorphine in chronic pain management due to its unique pharmacological properties, efficacy, and safety profile. Its ability to provide effective pain relief while minimizing the risks associated with traditional opioids makes it a valuable option for patients and clinicians alike. Future research should continue to explore and document the long-term effects and potential uses of buprenorphine in various pain management settings, ensuring that its benefits can be maximized for a broader range of patients.

Buprenorphine and Opioid Use Disorder Treatment

The treatment of OUD has evolved significantly with the introduction of medications like buprenorphine, which has proven to be a vital tool in the management of this chronic condition. Buprenorphine's pharmacological nuances allow it to mitigate dependency risks while effectively managing withdrawal symptoms and reducing opioid cravings.

Buprenorphine's efficacy in treating opioid dependence is well-supported by extensive research. Its mechanism as a partial agonist at mu-opioid receptors provides effective relief from withdrawal symptoms without producing the high associated with full agonists. This unique property decreases the likelihood of misuse and makes buprenorphine an attractive option for long-term treatment of opioid dependence. Studies have consistently shown that buprenorphine increases retention in treatment programs and decreases illicit opioid use, contributing to improved patient outcomes in recovery from OUD (Whelan and Remski, 2012).

Although methadone and buprenorphine both work well to treat overdose withdrawal, their pharmacological profiles and patient care strategies are very different. Because methadone carries a larger risk of dependency and overdose than other opioid agonists, it is usually delivered through specialized opioid treatment programs. On the other hand, because of its safer profile and decreased risk for abuse, buprenorphine can be administered in a greater variety of healthcare settings, including primary care.

Table 1: Comparison of buprenorphine and methadone in the treatment of opioid dependence

	Buprenorphine	**Methadone**
Receptor activity	Partial μ agonist	Full μ agonist
Half-life	36–48 hour	24–36 hour
Dosing frequency	Daily or alternate day	Daily
Abuse potential	Less	More
Overdose protection	Ceiling effect	No protective factors
Dependence severity	Mild–moderate	Severe
Withdrawal symptoms	Mild	Moderate/severe
Formulation	Tablet (risk of injection)	Oral liquid (less risk of injection)
Cost	Moderately expensive	Inexpensive

Source: "Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds," by Whelan, P. J., & Remski, K. 2012. J Neurosci Rural Pract, 3(1), 45-50.

Whelan and Remski (2012) provide a comparative analysis showing that while methadone may be slightly more effective at retaining patients in treatment, buprenorphine offers a better safety profile, with fewer risks of respiratory depression and a lower potential for misuse. This makes buprenorphine more suitable for less controlled outpatient settings, enhancing its accessibility and convenience for patients.

Furthermore, studies suggest that buprenorphine may be more effective in patients with a lower level of opioid dependency, whereas methadone could be favored for those with severe long-term dependencies due to its stronger opioid effects. This differentiation in use-case scenarios highlights the importance of tailored treatment approaches based on individual patient needs and histories (Whelan and Remski, 2012).

The impact of buprenorphine treatment extends beyond the physiological aspects of opioid withdrawal and dependency. It also significantly improves patients' quality of life by allowing more flexibility and normalcy in their daily activities. Unlike methadone, which often requires daily visits to treatment centers for dosing, buprenorphine can be taken at home, reducing the disruption to patients' lives and increasing their ability to maintain employment and social

relationships. This aspect of treatment is crucial for holistic recovery and long-term success in managing OUD (Whelan and Remski, 2012).

Despite the advantages of buprenorphine, there are significant challenges that limit its full potential in OUD treatment. Regulatory barriers, including the requirement for physicians to obtain special waivers to prescribe buprenorphine, restrict access to this medication. Additionally, the stigma associated with MAT persists, often influencing both patients' willingness to seek treatment and healthcare providers' willingness to offer it.

Buprenorphine represents a significant advancement in the treatment of OUD, offering a safer, more flexible, and often more acceptable alternative to methadone. However, maximizing its impact requires addressing regulatory, educational, and societal barriers that currently limit access to and acceptance of this vital treatment option. Continued research and policy efforts are needed to expand buprenorphine's role in OUD treatment, improve patient access, and reduce the stigma associated with its use.

Buprenorphine and Associated Stigma

The use of buprenorphine in the treatment of opioid use disorder and chronic pain management is often clouded by stigma. This stigma arises from various sources and significantly impacts patient access to treatment, healthcare provider practices, and public health policies. Understanding the nature and consequences of this stigma is crucial for improving treatment outcomes and reducing barriers to care.

The main source of stigma surrounding the usage of buprenorphine is its link to opiate addiction. According to Cheetham et al. (2022), stigma from society has an impact on people with OUD, resulting in biased beliefs that see MAT as nothing more than a drug replacement rather than an accepted medical intervention. Because of this social stigma, people diagnosed with OUD are often discouraged from getting treatment out of fear of prejudice or judgment.

In the healthcare setting, Dela-Cruz et al. (2023) highlighted the stigmatization from medical professionals, which can manifest as reluctance or refusal to prescribe buprenorphine. This reluctance often stems from a lack of familiarity with MAT, biases against people with substance use disorders, or misconceptions about the safety and efficacy of buprenorphine.

Stigma has an impact on people's willingness to seek treatment as well as the standard of care they get. Stigmatizing views among healthcare professionals may result in inadequate prescribing practices, such as underdosing, which may not adequately meet the patient's needs for opioid dependency or pain management (Cheetham et al., 2022; Dela-Cruz et al., 2023). Stigmatized patients may also experience inconsistent care, difficulty enrolling in treatment programs, or a lack of support from the medical community. This can exacerbate the cycle of addiction and stigma by having a negative impact on health outcomes and increasing the chance of relapsing (Dela-Cruz et al., 2023).

To combat the stigma associated with buprenorphine, targeted educational programs for healthcare providers and the public are essential. These programs should aim to dispel myths

URL: http://doi.org/10.14738/abr.1305.18834

about addiction and MAT, highlighting the scientific evidence supporting the efficacy and safety of buprenorphine as part of a comprehensive treatment approach (Cheetham et al.,2022).

Reducing stigma also requires policy interventions. Policies that support increased access to buprenorphine, streamline the prescription process, and shield patients from discrimination can help normalize MAT as a common medical practice. By taking these steps, more healthcare professionals would be inspired to join MAT, and more patients would be willing to participate in therapy without worrying about being stigmatized (Dela-Cruz et al., 2023).

The stigma associated with buprenorphine use is a significant barrier to effective treatment for opioid dependency and chronic pain management. By understanding and addressing the roots of this stigma, healthcare providers and policymakers can improve access to care, enhance the quality of treatment, and promote better health outcomes for individuals with OUD. Ongoing efforts to educate, advocate, and legislate are necessary to dismantle the stigma surrounding buprenorphine and enhance its acceptance both within the medical community and society at large.

Management Implications

Implications for Marketers:

Marketers can use the CDC guidelines as a trusted source to bolster educational campaigns about buprenorphine, emphasizing its role in pain management within the framework of safer opioid prescribing practices. The guidelines highlight the complexities of pain management and the need for careful assessment and treatment, which buprenorphine can address effectively due to its lower abuse potential compared to full opioid agonists. Highlighting these points can help reshape perceptions about buprenorphine, positioning it as a critical tool in the broader context of opioid stewardship and patient safety (Centers for Disease Control and Prevention, 2022).

The Centers for Disease Control's emphasis on minimizing opioid-related risks like addiction and overdose aligns well with buprenorphine's pharmacological profile. Marketing materials can focus on how buprenorphine meets the guidelines call for opioid therapies with lower risk profiles. This approach not only appeals to healthcare providers seeking to comply with best practices but also reassures patients about the safety of their treatment options.

The guidelines underscore the need for healthcare systems and payers to facilitate access to effective pain management therapies, including those like buprenorphine that potentially offer reduced risk of harm. Marketers can leverage this aspect to advocate for policies that support a broader use of buprenorphine, especially in systems restricted by stringent opioid prescription regulations. Engaging in policy discussions and forums citing the CDC guidelines can help influence healthcare policies to be more inclusive of buprenorphine as a preferred treatment option (Centers for Disease Control and Prevention, 2022).

Research-driven marketing strategies can be informed by and designed with the help of the extensive data provided in the CDC guidelines regarding the limitations of long-term opioid use for the management of chronic pain. With a solid evidence basis bolstering its efficacy and

safety, buprenorphine is a desirable alternative that can successfully address widespread concerns about opioid use raised by this study.

Implications for Scholars

Scholars have a pivotal role in advancing the understanding of buprenorphine's efficacy and safety in both OUD and chronic pain management. With ongoing debates about the optimal use of opioids, scholarly research can provide critical insights that help refine clinical guidelines and prescribing practices. Studies like those discussed provide a foundation, but further research is needed to explore long-term outcomes and the comparative effectiveness of buprenorphine against a broader spectrum of opioids across diverse patient populations (Whelan and Remski, 2012; Dela-Cruz et al., 2023).

Research addressing the stigma associated with buprenorphine use, as explored in Cheetham-2022 and Dela-cruz-2023, is crucial. Scholars can contribute by designing and implementing studies that measure the impact of educational interventions on reducing stigma among healthcare providers and the public. Additionally, qualitative research that explores the firsthand experiences of patients and healthcare providers can provide deeper insights into the barriers posed by stigma and how they can be overcome (Cheetham et al., 2022; Dela-Cruz et al., 2023).

Given the considerable influence of policy on the accessibility and utilization of buprenorphine, scholars can investigate the impact of existing policies and advocate for evidence-based policy changes. The work highlighted in Sivils-2022 shows the potential of scholarly research to inform policy debates and adjustments, particularly around the regulations governing buprenorphine prescribing. Research could focus on the outcomes of policy changes in different regions or settings, providing data that could help optimize regulations to enhance patient access and treatment outcomes (Silvia et al., 2022).

Scholars can also play a crucial role in developing educational programs aimed at healthcare providers and students in the medical and pharmaceutical fields. These programs should be designed based on the latest research findings to ensure they accurately reflect the current understanding of buprenorphine's benefits and risks. By improving education around buprenorphine, scholars can help ensure that future healthcare providers are better prepared to utilize this treatment effectively and compassionately.

The complexities of opioid addiction and chronic pain management require a multidisciplinary approach. Scholars in pharmacy, medicine, public health, and social sciences can collaborate to provide a holistic understanding of the issues surrounding buprenorphine use. This collaboration could lead to innovative solutions that address the medical, social, and psychological aspects of opioid use and pain management. Such collaborative efforts could also extend to include partnerships with policymakers, clinicians, and community organizations, fostering a comprehensive approach to tackling the opioid crisis. By engaging in these areas, scholars can significantly contribute to the body of knowledge on buprenorphine, supporting more informed clinical practices, more effective public health policies, and better outcomes for patients suffering from OUD and chronic pain. Each of these efforts not only advances academic understanding but also plays a direct role in improving public health and patient care.

URL: http://doi.org/10.14738/abr.1305.18834

Further Research

Addressing the stigma associated with buprenorphine use in the treatment of OUD and chronic pain management is critical for improving patient outcomes. One promising area of research involves applying the Health Belief Model (HBM) to understand and potentially mitigate the stigma that patients experience when considering or using buprenorphine.

The Health Belief Model, a well-established psychological model that explains and predicts health-related behaviors, can be a valuable tool in studying the factors that influence the acceptance and use of buprenorphine. HBM focuses on the perceptions of the severity of a health problem, the benefits of avoiding the risk, the barriers to taking a recommended health action, and the self-efficacy to perform such actions. By applying this model, researchers can systematically explore how individual beliefs about drug dependency and treatment influence decisions regarding the use of buprenorphine.

A proposed study could investigate how perceptions of severity (e.g., the serious consequences of OUD), susceptibility (individual risk of OUD), benefits (advantages of using buprenorphine), barriers (stigma and other obstacles), and self-efficacy (confidence in managing health with buprenorphine) affect a patient's decision to initiate and adhere to buprenorphine treatment. This research could include qualitative methods such as interviews and focus groups to gather in-depth insights into patient and healthcare provider attitudes, as well as quantitative surveys to measure these attitudes across larger populations.

Research findings using the HBM could inform targeted interventions to reduce stigma. For instance, if barriers such as misconceptions about buprenorphine's effectiveness or fears about societal judgment are prominent, these can be addressed through specific educational programs and public awareness campaigns. Additionally, understanding the role of self-efficacy could lead to the development of support mechanisms that empower patients to engage more confidently with their treatment options.

Scholars should also focus on how the outcomes of such studies can be integrated into clinical practice. Training programs based on research findings could be developed to educate healthcare providers on the psychological barriers that their patients might face and effective strategies to support their patients in overcoming these barriers.

Exploring the application of HBM in the context of buprenorphine use offers a structured approach to understanding and addressing the complex stigma associated with treatment for OUD and chronic pain. Future research in this area can not only provide deeper insights into patient behaviors and attitudes but also support the development of more effective clinical practices and public health policies that enhance the uptake and effectiveness of buprenorphine treatment.

This approach aligns with existing literature and emphasizes the need for a multifaceted strategy to combat stigma, as discussed in sources like Cheetham et al., (2022) and Dela-Cruz et al., (2023). Further exploration of these issues could significantly contribute to the literature on opioid treatment and stigma reduction, ultimately leading to improved health outcomes for individuals affected by OUD and chronic pain.

DISCUSSION

Throughout this comprehensive examination of buprenorphine, it has become evident that while buprenorphine holds substantial promise for both chronic pain management and OUD treatment, there are significant barriers to its full utilization, mainly driven by stigma and regulatory challenges. This multifaceted exploration has underscored the importance of addressing these issues through targeted research, educational campaigns, and policy reform.
The literature highlights buprenorphine's efficacy and safety in managing chronic pain and treating OUD. Studies suggest that buprenorphine is an effective and safer alternative to full agonist opioids due to its partial agonist properties at mu-opioid receptors, which result in a lower potential for abuse and overdose (Dalal et al., 2021; Ling et al., 2012). Its utility in OUD treatment is similarly supported by its ability to reduce cravings and withdrawal symptoms without the high associated with more potent opioids (Whelan and Remski, 2012).

The pervasive stigma associated with buprenorphine, both in contexts of pain management and opioid dependence treatment, significantly affects patient access to care and the willingness of healthcare providers to prescribe this medication. Addressing stigma is crucial, as it is a major barrier that undermines the potential benefits of buprenorphine (Cheetham et al., 2022; Dela-Cruz et al., 2023).

Marketers have the potential to reshape public and professional perceptions of buprenorphine through effective education and advocacy. By clearly communicating the benefits of buprenorphine and addressing common misconceptions, they can enhance patient and provider acceptance of this treatment option (Lawrence et al., 2022; Mujtaba et al., 2023). Meanwhile, scholars are tasked with conducting research that fills existing knowledge gaps, particularly regarding long-term outcomes and strategies to combat stigma (Silvis et al., 2022). HBM can be a powerful framework for addressing the barriers and stigma surrounding the use of buprenorphine in chronic pain management and OUD treatment. The model's core components, perceived severity, perceived susceptibility, perceived benefits, perceived barriers, cues to action, and self-efficacy, provide a structured approach to understanding and influencing patient behaviors, particularly in contexts where stigma and misinformation may significantly impact health outcomes (Jones et al., 2015; Orji et al., 2012).

In applying HBM to the current challenges with buprenorphine, we begin by examining how patients perceive the severity and susceptibility of their conditions, particularly chronic pain and OUD. Chronic pain is often seen as an inevitable part of life, especially in older populations, leading to a resignation that might discourage patients from seeking or adhering to treatment. Similarly, the stigma surrounding OUD can lead to a perception that the condition is a moral failing rather than a medical issue, further compounding patients' reluctance to seek help (Champion & Skinner, 2008). By leveraging HBM, interventions can be tailored to enhance patients' understanding of the serious consequences of untreated chronic pain and OUD, thereby elevating their perceived severity and susceptibility. This increased awareness can motivate patients to engage more proactively in their treatment (Carpenter, 2010).

Perceived benefits and barriers play a critical role in patients' decisions to start and continue buprenorphine therapy. Despite its proven efficacy, buprenorphine is often underutilized due to misconceptions about its effectiveness, the fear of becoming dependent, and the stigma

URL: http://doi.org/10.14738/abr.1305.18834

associated with its use (Jones et al., 2015). These barriers are often reinforced by the societal stigma surrounding buprenorphine prescription. The HBM suggests that addressing these barriers through targeted educational campaigns that highlight the benefits of buprenorphine, such as its lower risk of dependence compared to full agonist opioids and its dual role in pain management and OUD treatment, can help shift patient and provider perceptions.

Cues to action, another component of HBM, is essential in triggering the decision to adopt healthier behaviors. In buprenorphine, these cues could come from healthcare providers, public health campaigns, or even testimonials from patients who have successfully managed their conditions with buprenorphine. These cues can be particularly effective when personalized, addressing specific patient concerns and fears (Champion & Skinner, 2008). For example, a patient who fears societal judgment might be encouraged by stories of others who have overcome similar challenges, reinforcing the idea that successful treatment is achievable and socially acceptable.

Self-efficacy, the belief in one's ability to successfully engage in health-promoting behaviors, is perhaps the most crucial aspect of HBM in buprenorphine use. Patients who believe they can effectively manage their condition with buprenorphine are more likely to adhere to their treatment plans and experience better outcomes. Enhancing self-efficacy can be achieved through patient education, supportive counseling, and robust healthcare provider-patient relationships (Carpenter, 2010). When patients feel supported and informed, they are more likely to trust in their ability to manage their pain or OUD with buprenorphine.

The integration of HBM into buprenorphine-related interventions not only helps in reducing stigma but also provides a clear pathway for improving patient outcomes. By systematically addressing the components of the HBM, enhancing perceptions of severity and susceptibility, clarifying benefits while minimizing barriers, providing strong cues to action, and fostering self-efficacy, healthcare providers can significantly improve the acceptance and effectiveness of buprenorphine treatment (Jones et al., 2015).

In conclusion, buprenorphine represents a critical tool in the fight against opioid addiction and the management of chronic pain. By continuing to advocate for research, education, and policy changes, healthcare stakeholders can ensure that buprenorphine reaches its full potential as a cornerstone of opioid dependency treatment and pain management. This integrated approach will not only enhance clinical outcomes but also support broader public health goals in combating the opioid crisis.

Disclosure Statement: The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

Bish, A., Sutton, S., & Golombok, S. (2000). Predicting uptake of a routine cervical smear test: A comparison of the Health Belief Model and the Theory of Planned Behaviour. Psychology and Health, 15(1), 35-50. https://doi.org/10.1080/08870440008400288

Carpenter, C. J. (2010). A meta-analysis of the effectiveness of health belief model variables in predicting behavior. Health Communication, 25(8), 661-669. https://doi.org/10.1080/10410236.2010.521906

Centers for Disease Control and Prevention. (2022). Clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recommendations and Reports, 71(3). https://www.cdc.gov/mmwr/volumes/71/rr/rr7103a1.htm

Champion, V. L., & Skinner, C. S. (2008). The Health Belief Model. In K. Glanz, B. K. Rimer, & K. Viswanath (Eds.), Health Behavior and Health Education: Theory, Research, and Practice (4th ed., pp. 45-65). Jossey-Bass.

Cheetham, A., Picco, L., Barnett, A., Lubman, D. I., & Nielsen, S. (2022). The Impact of Stigma on People with Opioid Use Disorder, Opioid Treatment, and Policy. Substance Abuse and Rehabilitation, 13, 1-12. https://doi.org/10.2147/sar.s304566

Chen, K. Y., Chen, L., & Mao, J. (2014). Buprenorphine–Naloxone Therapy in Pain Management. Anesthesiology, 120(5), 1262-1274. https://doi.org/10.1097/aln.0000000000000170

Dalal, S., Chitneni, A., Berger, A. A., Orhurhu, V., Dar, B., Kramer, B., Nguyen, A., Pruit, J., Halsted, C., Kaye, A. D., & Hasoon, J. (2021). Buprenorphine for Chronic Pain: A Safer Alternative to Traditional Opioids. Health Psychology Research, 9(1). https://doi.org/10.52965/001c.27241

Dela Cruz, A. M., Karns-Wright, T., Kahalnik, F., Walker, R., Lanham, H. J., Potter, J. S., & Trivedi, M. H. (2023). Stigma towards opioid use disorder in primary care remain a barrier to integrating software-based measurement-based care. BMC Psychiatry, 23(1). https://doi.org/10.1186/s12888-023-05267-w

Dowell, D., Ragan, K. R., Jones, C. M., Baldwin, G. T., & Chou, R. (2022). CDC Clinical Practice Guideline for Prescribing Opioids for Pain—United States, 2022. Morbidity and Mortality Weekly Report. Recommendations and Reports, 71(3), 1–95. https://doi.org/10.15585/mmwr.rr7103a1

Hale, M., Garofoli, M., & Raffa, R. B. (2021). Benefit-Risk Analysis of Buprenorphine for Pain Management. Journal of Pain Research, 14, 1359-1369. https://doi.org/10.2147/jpr.s305146

Heidbreder, C., Fudala, P. J., & Greenwald, M. K. (2023). History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug Alcohol Depend Rep, 6, 100133. https://doi.org/10.1016/j.dadr.2023.100133

Janet Ho, J., Jones, K. F., Sager, Z., Neale, K., Childers, J. W., Loggers, E., & Merlin, J. S. (2022). Barriers to Buprenorphine Prescribing for Opioid Use Disorder in Hospice and Palliative Care. Journal of Pain and Symptom Management, 64(2), 119-127. https://doi.org/10.1016/j.jpainsymman.2022.05.004

Javed, S., Batool, N., Kamal, N., & Mujtaba, B. G. (2024). Impediments to physicians' workplace contentment and wellness: A multifaceted qualitative inquiry. Health Economics and Management Review, 5(3), 20-39. https://doi.org/10.61093/hem.2024.3-02.

Johnson, R. E., Fudala, P. J., & Payne, R. (2005). Buprenorphine: Considerations for Pain Management. Journal of Pain and Symptom Management, 29(3), 297-326. https://doi.org/10.1016/j.jpainsymman.2004.07.005

Jones, C. L., Jensen, J. D., Scherr, C. L., Brown, N. R., Christy, K., & Weaver, J. (2015). The Health Belief Model as an explanatory framework in communication research: Exploring parallel, serial, and moderated mediation. Health Communication, 30(6), 566-576. https://doi.org/10.1080/10410236.2013.873363

Jones, C. M., Olsen, Y., Ali, M. M., Sherry, T. B., McAninch, J., Creedon, T., Juliana, P., Jacobus-Kantor, L., Baillieu, R., Diallo, M. M., Thomas, A., Gandotra, N., Sokolowska, M., Ling, S., & Compton, W. (2023). Characteristics and Prescribing Patterns of Clinicians Waivered to Prescribe Buprenorphine for Opioid Use Disorder Before and After Release of New Practice Guidelines. JAMA Health Forum, 4(7), e231982. https://doi.org/10.1001/jamahealthforum.2023.1982

Khanfar, N. M., Nafei, W. A., & Mujtaba, B. G. (2024). Impact of digital twinning on health service quality and sustainable competitive advantage: A study with private hospital professionals. Health Economics and Management Review, 5(4), 126-141. https://doi.org/10.61093/hem.2024.4-08.

Kumar, R., Viswanath, O., & Abdolreza Saadabadi. (2023). Buprenorphine. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK459126/

Lawrence, E., Tworoger, L.C., Ruppel, C.P., and Mujtaba, B.G. (2022). A Team-Based Roadmap for Healthcare Change in a Turbulent Environment: A Longitudinal Study of a Not-for-Profit Hospital Transitioning into a for-Profit Organization. Public Organization Review, 22, 967-985. https://doi.org/10.1007/s11115-021-00544-2

Lazaridou, A., Paschali, M., Edwards, R. R., & Gilligan, C. (2020). Is Buprenorphine Effective for Chronic Pain? A Systematic Review and Meta-analysis. Pain Medicine, 21(12), 3691-3699. https://doi.org/10.1093/pm/pnaa089

Ling, Walter, Hillhouse, Maureen, Jenkins, Jessica, Miotto, Karen, Torrington, Matthew & Chapleo, Christopher. (2012). Comparisons of Analgesic Potency and Side Effects of Buprenorphine and Buprenorphine With Ultra-low-dose Naloxone. Journal of Addiction Medicine, 6, 118-123. https://doi.org/10.1097/ADM.0b013e31824fceca

Mujtaba, B. G. and Meyer, C. (2022). Checklist for Professional Communication: A Path to a Healthy Personality, Reflective Mindfulness, and Self-Development Management. Health Economics and Management Review, 3(3), 99-108. https://doi.org/10.21272/hem.2022.3-10

Mujtaba, B.G., Kaifi, B.A., & Lawrence, E. (2023). Safety mandates, legal requirements, and management practices to provide employees with a safe and healthful work environment. International Journal of Occupational and Environmental Safety, 7(2), 1-19. DOI: 10.24840/2184-0954_007-002_002116

Orji, R., Vassileva, J., & Mandryk, R. (2012). Towards an effective health interventions design: An extension of the Health Belief Model. Online Journal of Public Health Informatics, 4(3). https://doi.org/10.5210/ojphi.v4i3.4321

Sivils, A., Lyell, P., Wang, J. Q., & Chu, X.-P. (2022). Suboxone: History, controversy, and open questions. Frontiers in Psychiatry, 13. https://doi.org/10.3389/fpsyt.2022.1046648

Steenhof, N., & Ng, K. (2024). Buprenorphine-naloxone in chronic pain: Overcoming stigma for safer opioid management. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada, 157(1), 7-9. https://doi.org/10.1177/17151635231214508

Substance Abuse and Mental Health Services Administration. (2024). Buprenorphine. https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions/buprenorphine#:~:text=Generic%20Buprenorphine%2Fnaloxone%20sublingual%20tablets,Buprenorphine%20sublingual%20tablets%20(Subutex)

U.S. Food and Drug Administration. (2023). Information about Medication-Assisted Treatment. https://www.fda.gov/drugs/information-drug-class/information-about-medication-assisted-treatment-mat

Whelan, P. J., & Remski, K. (2012). Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds. J Neurosci Rural Pract, 3(1), 45-50. https://doi.org/10.4103/0976-3147.91934